{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:37:19Z","timestamp":1783741039775,"version":"3.55.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,2]]},"DOI":"10.7759\/cureus.87150","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:06:43Z","timestamp":1751447203000},"source":"Crossref","is-referenced-by-count":1,"title":["Breathless Balance: Navigating Pembrolizumab-Induced Pneumonitis and Congestive Heart Failure (CHF) Exacerbation"],"prefix":"10.7759","author":[{"given":"Philip","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsalan","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Akl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Litinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14605","article-title":"Pembrolizumab-induced myocarditis: a systematic review of case reports","volume":"42","author":"Hasan W","year":"2024","unstructured":"Hasan W, Eysa A, Chauhan D, et al.. Pembrolizumab-induced myocarditis: a systematic review of case reports. J Clin Oncol. 2024, 42:14605. 10.1200\/JCO.2024.42.16_suppl.e14605","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli H","year":"2015","unstructured":"L\u00e4ubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015, 3:11. 10.1186\/s40425-015-0057-1","journal-title":"J Immunother Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.07.3094","article-title":"Pneumonitis: is it pembrolizumab or COVID-19?","volume":"164","author":"Patel V","year":"2023","unstructured":"Patel V, Patel S, Pacheco L, et al.. Pneumonitis: is it pembrolizumab or COVID-19?. Chest. 2023, 164:2251. 10.1016\/j.chest.2023.07.3094","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00378.2023","article-title":"Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications","volume":"325","author":"Banerjee A","year":"2023","unstructured":"Banerjee A, Narasimhulu CA, Singla DK. Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications. Am J Physiol Heart Circ Physiol. 2023, 325:H751-67. 10.1152\/ajpheart.00378.2023","journal-title":"Am J Physiol Heart Circ Physiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/381203-breathless-balance-navigating-pembrolizumab-induced-pneumonitis-and-congestive-heart-failure-chf-exacerbation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:06:44Z","timestamp":1751447204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/381203-breathless-balance-navigating-pembrolizumab-induced-pneumonitis-and-congestive-heart-failure-chf-exacerbation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.87150","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}